Aldeyra Therapeutics (NASDAQ:ALDX) Posts Earnings Results, Misses Estimates By $0.30 EPS

Aldeyra Therapeutics (NASDAQ:ALDX) released its quarterly earnings results on Friday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.30), Zacks reports.

Aldeyra Therapeutics Stock Down 19.4 %

ALDX traded down $1.23 during midday trading on Friday, reaching $5.11. 1,820,630 shares of the company’s stock were exchanged, compared to its average volume of 397,867. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.92. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The business’s 50-day moving average price is $5.48 and its 200 day moving average price is $5.38.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.